Economic Data - The People's Bank of China will release January CPI and PPI on February 11 [1] - The National Bureau of Statistics will publish the monthly report on January commodity residential sales price index on February 13 [1] - Financial data including January social financing and new RMB loans will also be released next week [1] - In the US, December retail sales month-on-month will be announced on February 10, followed by January unemployment rate and non-farm employment data on February 11 [1] Earnings Reports - The US earnings season continues with several notable companies reporting next week, including BP, Barclays, Marriott, Coca-Cola, and AstraZeneca on February 10 [2] - Other companies such as NetEase, Youdao, and Total will report on February 11, while TripAdvisor and Hyatt will report on February 12 [2] - In Hong Kong, SMIC will report earnings on February 10, followed by Budweiser APAC and NetEase Cloud Music on February 11 [2] New Stock Issuance - One new stock, Tongbao Optoelectronics, will be available for subscription on February 9, with Ai De Technology listing on the Beijing Stock Exchange on February 10 [2] - Several new stocks will list in Hong Kong, including Lanke Technology on February 9 and Aixin Yuanzhi on February 10 [2] Stock Unlocking - A total of 33 restricted stocks will be unlocked next week, with a total market value exceeding 36 billion yuan, led by Hunan YN with 24.096 billion yuan [3][10] Central Bank Operations - The central bank will have 4.055 billion yuan of reverse repos maturing next week, with specific amounts maturing each day [3][10] Government Bonds - The Ministry of Finance will issue the first phase of RMB government bonds in Hong Kong on February 11, with a scale of 14 billion yuan [13]

Group 1 - The fourth quarter earnings season is ongoing, with significant results from major companies like Alphabet, Amazon, AMD, Qualcomm, and Palantir [1] - As of February 6, 59% of S&P 500 companies have reported their fourth quarter results, with analysts estimating a 13% increase in earnings per share, marking the 10th consecutive quarter of annual earnings growth for the index [2][4] - Analysts initially expected an 8.3% increase in earnings per share for the fourth quarter, a decrease from the previous quarter's 13.6% growth rate, but have since raised expectations, particularly for tech companies [4] Group 2 - Major capital expenditures by Big Tech are influencing the AI trade, with ongoing themes from 2025, such as artificial intelligence and economic policies, continuing to impact investor sentiment [5] - Upcoming earnings reports are anticipated from companies including Coca-Cola, Spotify, Robinhood, Lyft, Ford, Rivian, Moderna, Airbnb, and Coinbase [6]

Core Viewpoint - Moderna is facing a $5 billion patent-infringement lawsuit regarding its COVID-19 vaccine, Spikevax, which allegedly infringes on lipid nanoparticle technology patented by Genevant Sciences and Arbutus Biopharma [1]. Legal Proceedings - U.S. District Judge Joshua D. Wolson denied Moderna's request for summary judgment, allowing the jury to decide on the patent infringement claims [1]. - The judge emphasized the importance of patent law, stating that copying inventions is not permissible, even with expedited vaccine development under "Operation Warp Speed" [2]. Technical Aspects of the Case - The lawsuit centers on the delivery mechanism of the vaccine, specifically how Messenger RNA (mRNA) is protected by lipid nanoparticles, which are claimed to be patented by the plaintiffs [3]. - Arbutus Biopharma asserts that their research involved identifying specific "molar ratios" of lipids necessary for the vaccine's safety and efficacy [3]. Government Immunity Defense - Moderna's defense strategy included invoking section 1498, which protects government contractors from patent infringement lawsuits, arguing that the vaccine was developed under a federal program [4]. - However, the judge ruled that section 1498 applies only if the product was intended for the government itself, not the general public, which could expose Moderna to $5 billion in damages [5]. Patent Validity and Infringement - The jury will also evaluate the scientific validity of the patent claims and the concept of "literal infringement," with the judge allowing certain technical requests regarding how patent infringement can be established [6].

Moderna (MRNA) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.Over the past month, shares of this biotechnology company have returned +20.7%, compared to the Zacks S&P 500 composite's -1.5% change. During this period, the Zacks Medical - Biomedical and Genetics industry, which Moderna falls in, has gained 21.3%. The key question now is: What could be the stock's f ...

Group 1 - Moderna, Inc. is highlighted as a noteworthy stock in the S&P 500, with a significant increase of nearly 50% in January [1] - The company experienced a dramatic decline of 95% from its peak in 2021 to its lows in November 2022, but has since nearly doubled from those lows [1] - Moderna is expected to return to revenue growth in 2026 for the first time since 2021, following a positive investor day event [1] Group 2 - Moderna specializes in mRNA medicines and vaccines for illnesses such as flu and COVID-19, and is also developing treatments for cancer and rare diseases [1]

Core Viewpoint - Defiance ETFs has launched the Defiance Daily Target 2X Long MRNA ETF (MRNX), aimed at providing active traders with leveraged exposure to Moderna, Inc. and its mRNA-based innovations in biotechnology and life sciences [1][2]. Investment Objective - The Fund aims to achieve daily investment results of 200% of the daily percentage change in the share price of Moderna, Inc., focusing solely on short-term trading strategies [3]. Underlying Stock - Moderna, Inc. is a biotechnology company specializing in the development of mRNA-based therapeutics and vaccines, addressing various disease areas including infectious diseases [4]. Fund Characteristics - The ETF is not a direct investment in Moderna, Inc. and is designed for knowledgeable investors who understand the risks associated with leveraged investments [5][6]. - The Fund's performance is subject to daily rebalancing, which may lead to significant differences in returns over periods longer than one day due to compounding effects [13][14]. Risks Associated with the Fund - The Fund's strategy involves swap agreements and options contracts, exposing it to risks similar to owning shares of Moderna, Inc., including potential declines in share price [9][11]. - The Fund is classified as non-diversified, which may increase sensitivity to adverse developments affecting Moderna, Inc. [18]. - High portfolio turnover is expected due to daily rebalancing, potentially increasing transaction costs and tax implications for investors [19].

Core Insights - The company has achieved significant breakthroughs in cancer treatment through its partnership with Merck, focusing on individualized therapies for melanoma and other cancers [2][4][6] - The phase two study for the melanoma treatment showed a 50% improvement in recurrence-free survival compared to existing treatments, with plans for a phase three study and potential FDA filing in 2027 [4][37] - The company is expanding its research into various cancers, including lung, kidney, bladder, gastric, and pancreatic cancers, with nine ongoing studies [6][7] Cancer Treatment Developments - The individualized treatment approach allows for tailored therapies based on the patient's specific cancer profile, with a turnaround time of approximately 30 days [3][4] - The safety profile of the new treatment is comparable to existing therapies, presenting no additional risks or side effects [7] - The company anticipates positive results from ongoing studies, which could lead to further FDA approvals and market launches [17][38] Vaccine Business and Market Strategy - The company expects 2027 to be a pivotal growth year, driven by opportunities in the $1.75 billion respiratory virus vaccine market in the EU and long-term partnerships in Latin America [8][39] - The company has three FDA-approved products and aims to diversify its portfolio with additional approvals expected this year [17][19] - Cost-cutting measures have been implemented, with $2 billion in costs reduced in the previous fiscal year, while still investing in future innovations [19][40] Collaboration and Innovation - The company is collaborating with Ricardati to advance treatments for rare metabolic disorders, leveraging mRNA technology [25][27] - The focus on innovation is critical for sustaining the industry, with a call for global contributions to support ongoing research and development [30][31][34] - The company emphasizes the importance of patent protection to encourage investment in new medicines, highlighting the long development timelines and high failure rates in clinical trials [33][34]

Core Insights - Moderna, Inc. is a biotechnology company based in Cambridge, Massachusetts, with a market cap of $17.2 billion, known for its messenger RNA medicines and COVID-19 vaccine, and is expanding its pipeline in various therapeutic areas [1] Performance Summary - Over the past 52 weeks, Moderna's shares have increased by 19.3%, outperforming the S&P 500 Index, which rose by 15.5%. Year-to-date, the stock is up 47.9%, while the S&P 500 has only gained 1.9% [2] - Despite this, Moderna has underperformed compared to the iShares Biotechnology ETF, which saw a 26.2% increase over the same period, although it has outperformed the ETF's 3.1% year-to-date return [3] Recent Developments - On January 21, shares surged by 15.8% following positive results from a five-year follow-up study of an experimental skin cancer vaccine in collaboration with Merck, showing a 49% reduction in recurrence or death risk for high-risk melanoma patients [5] Financial Outlook - Analysts project that Moderna's loss per share for the current fiscal year will narrow by 10.9% year-over-year to $7.90. The company has consistently exceeded consensus earnings estimates in the last four quarters [6] - The consensus rating among 24 analysts is a "Hold," with two "Strong Buy," 19 "Hold," one "Moderate Sell," and two "Strong Sell" ratings [6] Analyst Ratings and Price Targets - Edward Tenthoff from Piper Sandler Companies maintains a "Buy" rating with a price target of $63, indicating a potential upside of 44.3%. The current trading price is above the mean price target of $37.40, while the highest price target of $135 suggests a 209.1% premium [8]

分组1 - Arbutus Biopharma Corporation (ABUS) has experienced a decline of approximately 10% in its stock price over the past month due to a patent dispute with Moderna [1] - The company is involved in the biotechnology sector, focusing on innovative drug development and unique therapeutic approaches [1] - The analyst emphasizes the importance of evaluating the scientific basis of drug candidates, competitive landscape, clinical trial design, and market opportunities while considering financial fundamentals [1]

Whales with a lot of money to spend have taken a noticeably bullish stance on Moderna.Looking at options history for Moderna (NASDAQ:MRNA) we detected 26 trades.If we consider the specifics of each trade, it is accurate to state that 50% of the investors opened trades with bullish expectations and 38% with bearish.From the overall spotted trades, 4 are puts, for a total amount of $161,480 and 22, calls, for a total amount of $1,274,892.Predicted Price RangeAnalyzing the Volume and Open Interest in these con ...